Androgen receptor gene CAG repeat polymorphism in women with polycystic ovary syndrome
|
|
- Sheila McCarthy
- 6 years ago
- Views:
Transcription
1 Androgen receptor gene CAG repeat polymorphism in women with polycystic ovary syndrome Jin Ju Kim, M.D., a Seon Ha Choung, B.S., a Young Min Choi, M.D., a,b Sang Ho Yoon, M.D., c Seok Hyun Kim, M.D., a,b and Shin Yong Moon, M.D. a,b a Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul; b Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine, Seoul; and c Department of Obstetrics and Gynecology, Dongguk University International Hospital, Goyang, South Korea Objective: To evaluate the role of the androgen receptor (AR) gene CAG repeat in women with polycystic ovary syndrome (PCOS). Design: Case control study. Setting: University department of obstetrics and gynecology. Patient(s): Women with (n ¼ 114) or without (n ¼ 205) PCOS. Intervention(s): Peripheral blood sampling was done for DNA analysis and serum hormone measurements. Main Outcome Measure(s): CAG repeat length and serum androgen levels. Result(s): No statistically significant CAG repeat length differences were found between patients and controls. We conducted a detailed analysis after dividing PCOS patients according to their free testosterone levels. The high free testosterone group had a statistically significantly longer mean biallelic average ( vs ), short ( vs ), and long ( vs ) allelic lengths than the normal free testosterone group. In PCOS patients, a statistically significant correlation was found between biallelic average length and free testosterone concentration, either unadjusted or after adjustment. Conclusion(s): The AR gene CAG repeat polymorphism may contribute to the serum concentration of free testosterone in PCOS patients. A subset of PCOS patients with relatively longer CAG repeats (less AR activity) tended to show a higher serum androgen concentration. (Fertil Steril Ò 2008;90: Ó2008 by American Society for Reproductive Medicine.) Key Words: Androgen receptor, CAG repeat, polycystic ovary syndrome Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age, with a prevalence that varies from 4% to 7% (1, 2), and hyperandrogenism is a central feature. Androgens act through the androgen receptor (AR), which belongs to the nuclear receptor superfamily of transcription factors. Like other steroid receptors, the AR protein has three major domains: an N-terminal transactivation domain, a DNA-binding domain, and an androgenbinding domain. The transactivation activity of the receptor resides in its N-terminal domain. The AR gene, located on Xq , is composed of eight exons and is known to show more frequent sequence variation than other steroid receptor genes (3). In particular, its N- terminal transactivation domain contains a polyglutamine stretch that is coded by a CAG triplet of polymorphic length, beginning at codon 58 in exon 1. The inverse correlation between the number of CAG repeats and AR function has been described in many in vivo and in vitro studies (4 6). Received May 9, 2007; revised and accepted October 25, Supported by a grant from Seoul National University Hospital Research Fund (# ), Seoul, South Korea. Reprint requests: Young Min Choi, M.D., Department of Obstetrics & Gynecology, The Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University College of Medicine, 28 Yungun-dong, Chongno-ku, Seoul , South Korea (FAX: ; ymchoi@snu.ac.kr). The CAG repeat length polymorphism has been related to several diseases associated with low or high androgenic activity in both men and women. Shorter CAG tracts, a more transcriptionally active feature, have been associated with increased prostate cancer risk (7 9), higher cancer grade at diagnosis (10), and earlier onset in Caucasians (11). On the other hand, longer CAG repeat lengths appear to result in reduced AR activity. Abnormal elongation of CAG repeat number (>40 CAG repeats) has been linked to spinal and bulbar muscular atrophy (Kennedy disease), which is also associated with androgen insensitivity, decreased virilization, testicular atrophy, reduced sperm production, and infertility (12). Although within the normal polymorphic range, some studies have shown that relatively long tracts (R28 CAG repeats) are associated with an increased risk of male infertility due to impaired sperm production (5, 13). In men, it also has been reported that serum androgen levels are modulated by AR activity based upon the length of its polyglutamine tract: free testosterone increased with an increase in CAG repeat length (14). Data on the functional importance of the CAG repeat in women is sparse, but conditions including hirsutism (15), androgenic alopecia (16), and breast cancer (17) have been studied. Recent studies have shown an association between CAG repeat length and the subset of anovulatory patients with low serum androgen levels (18). Though the etiology of PCOS has not been elucidated, a number of studies have suggested that genetic factors 2318 Fertility and Sterility â Vol. 90, No. 6, December /08/$34.00 Copyright ª2008 American Society for Reproductive Medicine, Published by Elsevier Inc. doi: /j.fertnstert
2 play important roles in its etiology and pathogenesis (19, 20). Moreover, hyperandrogenism is a core feature of PCOS, and candidate genes that predispose an individual to the development of PCOS include the AR gene. The present study aimed to evaluate whether there is a difference in the AR gene CAG repeat length between PCOS patients and controls. We also assessed whether serum androgen levels are affected by AR activity in women with PCOS. MATERIALS AND METHODS Subjects We recruited 114 PCOS patients at the Department of Obstetrics and Gynecology at Seoul National University Hospital from 2004 to A diagnosis of PCOS was based on the 2003 American Society for Reproductive Medicine/European Society for Human Reproduction and Embryology (ASRM/ESHRE) consensus meeting guideline (21). Hirsutism was defined as a score of 8 or more on the Ferriman Gallwey scale (22), and oligoovulation was defined as a menstrual cycle of more than 35 days. None of the patients had features of Cushing disease or drug-induced hirsutism. The controls were 205 healthy premenopausal women. Among them, 106 women were patients being treated for uterine, tubal, or male factor infertility. The remaining 99 control women visited our outpatient clinic for an annual Papanicolaou smear test as a part of a cancer screening. The 2003 Rotterdam criteria were used to exclude PCOS in the controls before they entered the study. All control women had regular menstrual cycles (21 to 35 days) and Ferriman Gallwey scores below 8. They all had a transvaginal pelvic ultrasound examination performed to evaluate ovarian morphology and were excluded if they had polycystic ovary morphologic features. The patients and controls had not taken hormone medications, including oral contraceptives, for at least 6 months, and all the participants were screened to exclude hyperprolactinemia and thyroid dysfunction. The review board for human research of Seoul National University Hospital approved this project, and written informed consent was obtained from each woman. Hormonal Assays Biochemical data were available only for PCOS patients. Serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E 2 ) were measured on cycle day 3 of the follicular phase or during the period of amenorrhea in amenorrheic PCOS patients. Serum total testosterone (reference range: ng/ml), 17-hydroxyprogesterone (17-OHP) (reference range: ng/ml), dehydroepiandrosterone sulfate (DHEAS) (reference range: ng/ml), and sex hormone binding globulin (SHBG) (reference range: nmol/l) were measured using commercial kits (Diagnostic Products Corporation, Los Angeles, CA). Free testosterone was also directly measured by the radioimmunoassay (RIA) method using the same commercial kits (Diagnostic Products Corporation). For free testosterone, intra-assay and interassay coefficients of variation were less than 17% (intra-assay) and 8.0% to 18.3% (interassay), according to the manufacturer. All PCOS patients were assessed for glucose tolerance and insulin resistance with measurement of fasting and 2-hour glucose and insulin levels after a 75-g-glucose load. Plasma insulin (reference range: 2 25 mu/ml) was measured using commercial kits (BioSource Europe S.A., Nivelles, Belgium) with an intra-assay variation of 1.6% to 2.2% and inter-assay variation of 6.1% to 6.5%. In addition, the homeostatic model assessment (HOMA) was calculated as follows: HOMA ¼ (mg/dl glucose) (mu/ml insulin)/405. Polymerase Chain Reaction Genomic DNA was isolated and extracted from peripheral blood leukocytes using Wizard DNA extraction kits (Promega, Madison, WI). The total volume of the polymerase chain reaction (PCR) reaction mixture was 25 ml and contained 0.05 mg of genomic DNA, 10 mm Tris-HCl, ph 8.3, 50 mm KCl, 1.5 mm MgCl 2, 200 mm dntps (deoxynucleotide triphosphates), IU of Taq polymerase (Takara, Shiga, Japan), and 0.08 mm of each upstream and downstream primer. The oligonucleotide primers used for PCR were as follows: upstream primer 6FAM-5 0 TGC GCG AAG TGA TCC AGA AC3 0, and downstream primer 5 0 CTT GGG GAG AAC CAT CCT CA3 0. Following an initial denaturation step (5 minutes at 94 C), samples were subjected to 35 cycles of PCR at 95 C for 1 minute, 60 C for 1 minute, and 72 C for 1 minute with a final extension of 10 minutes at 72 C. The PCR product sizes were determined using GeneScan software (Perkin Elmer Applied Biosystems, Foster City, CA). The number of CAG repeats was calculated in relation to a series of standards obtained by automatic sequencing in three homozygous subjects. Statistical Analysis The AR gene CAG repeat length distributions were compared in PCOS patients and controls. Because two X-linked AR alleles are present, we adopted three modes of allele representation: using the mean value of the two alleles (biallelic averages) in each person, and using the short and long alleles of each patient separately. Because a subset (30% to 50%) of PCOS patients have normal serum androgen concentrations (23) and it has been shown that these patients may have an AR gene with a low number of CAG repeats (more active AR) (18), the patients were categorized into high free testosterone and normal free testosterone groups using a free testosterone cut-off value of 2.0 pg/ml (24). The CAG repeat lengths of the AR gene and other continuous variables were compared using the Student s t-test or Mann-Whitney U test. Correlation analysis was performed using Pearson s correlation coefficient. To explore the effect of the AR gene CAG repeat length on free testosterone concentration, a multiple linear regression model was Fertility and Sterility â 2319
3 constructed with free testosterone as a dependent variable and age, body mass index, HOMA, LH/FSH ratio, and biallelic average repeat length as independent variables. All data analyses were done using SPSS software (version 12.0; SPSS Inc., Chicago, IL). In all tests, P<.05 was considered statistically significant. Continuous data are reported as mean standard deviation (SD). RESULTS The AR Gene CAG Repeat Length Polymorphism in PCOS Patients and Controls The mean age of PCOS patients was statistically significantly lower ( vs years, P<.001) and mean body mass index was statistically significantly higher ( vs , P¼.017) than controls. The CAG repeats were successfully determined in all subjects. Allele sizes ranged from 14 to 31 among the PCOS patients, and from 12 to 32 among controls, which reflects the normal polymorphic range (11 38) reported for Chinese women (18). No differences were found in the mean numbers of CAG repeats between PCOS patients and controls, whether analyzed using biallelic averages ( in PCOS vs in controls) or separately for short ( in PCOS vs in controls) and long alleles ( in PCOS vs in controls). The AR Gene CAG Repeat Length Polymorphism in Normal and High Free Testosterone PCOS Groups The clinical and endocrine characteristics of the PCOS patients are depicted in Table 1. They were categorized into a high free testosterone group and a normal free testosterone group using a free testosterone cut-off value of 2.0 pg/ml (24). Examination of allele distributions revealed statistically significant differences in the AR gene CAG repeat length between these two groups (Table 2). The high free testosterone women had statistically significantly greater mean lengths than patients with normal free testosterone, as determined using biallelic averages ( vs , P¼.006) and short ( vs , P¼.046) and long alleles ( vs , P¼.013). In addition, alleles shorter than 16 repeats were recorded only in the normal free testosterone group, and the longest alleles (more than 30 repeats) were found only in the high free testosterone group. No differences were observed between the two groups for body mass index, waist-to-hip ratio, LH, FSH, SHBG, HOMA, postprandial 2-hour glucose, and insulin circulating levels, suggesting the differences observed above were not likely to be due to chance. Pearson s correlation analysis revealed a statistically significant correlation between free testosterone and biallelic average CAG repeat length (r ¼ 0.309, P¼.002). To analyze the impact of the AR gene CAG repeat length on free testosterone, a multiple linear regression model was constructed with free testosterone as a dependent variable (Table 3). A positive correlation was observed between TABLE 1 Clinical and biochemical features of the PCOS patients (n [ 114). Characteristic Value Age (years) Body mass index (kg/m 2 ) Waist-to-hip ratio Hirsutism score Total testosterone (ng/ml) Free testosterone (pg/ml) OHP (ng/ml) SHBG (nmol/l) DHEAS (ng/ml) LH (miu/ml) FSH (miu/ml) LH/FSH ratio E 2 (pg/ml) FBS (mg/dl) Fasting insulin (mu/ml) HOMA Postprandial 2-hour glucose (mg/dl) Postprandial 2-hour insulin (mu/ml) Note: All values are mean SD. 17-OHP, 17-hydroxyprogesterone; DHEAS, dehydroepiandrosterone sulfate; E 2, estradiol; FBS, fasting plasma glucose; FSH, follicle-stimulating hormone; HOMA, homeostatic model assessment; LH, luteinizing hormone; SHBG, sex hormone binding globulin. Kim. AR gene CAG repeats in PCOS. Fertil Steril CAG repeat length and free testosterone concentration, either unadjusted or after adjustment for age, body mass index, LH/FSH ratio, and HOMA (using centered data to avoid high multicollinearity). DISCUSSION Our study determined whether the pattern of (CAG) n polymorphism differed between normal women and women with PCOS and evaluated the relationship between CAG repeat and serum androgen levels in PCOS patients. According to our data, the AR gene exon 1 (CAG) n repeat length distribution in PCOS patients was not different from that of controls, indicating that the AR gene is not a major determinant of PCOS. However, more detailed analysis, performed after dividing PCOS patients into two groups according to free testosterone concentration, revealed statistically significant differences. The high free testosterone group had a statistically significantly longer mean biallelic average ( vs , P¼.006) and short ( vs., , P¼.046) and long ( vs , P¼.013) allelic lengths than the normal free testosterone group. However, the 2320 Kim et al. AR gene CAG repeats in PCOS Vol. 90, No. 6, December 2008
4 TABLE 2 Clinical features, biochemical variables and the AR exon 1 (CAG) n repeat lengths in polycystic ovary syndrome patients with below or above normal free testosterone levels. Normal free T (n [ 64) High free T (n [ 38) P value a Age (years) NS Body mass NS index (kg/m 2 ) Waist-to-hip ratio NS Hirsutism score Total testosterone (ng/ml) <.001 Free testosterone (pg/ml) < OHP (ng/ml) SHBG (nmol/l) NS DHEAS (ng/ml) <.001 LH (miu/ml) NS FSH (miu/ml) NS LH/FSH ratio NS E 2 (pg/ml) NS FBS (mg/dl) NS Fasting insulin (mu/ml) NS HOMA NS Postprandial 2-hour glucose NS (mg/dl) Postprandial 2-hour insulin (mu/ NS ml) CAG repeat CAG repeat (short allele) CAG repeat (long allele) Note: All values are mean SD. 17-OHP, 17-hydroxyprogesterone; DHEAS, dehydroepiandrosterone sulfate; E 2, estradiol; FBS, fasting plasma glucose; FSH, follicle-stimulating hormone; HOMA, homeostatic model assessment; LH, luteinizing hormone; NS, not statistically significant; SHBG, sex hormone binding globulin. a Student s t-test. Kim. AR gene CAG repeats in PCOS. Fertil Steril CAG length differences were only about one repeat for all alleles analyzed. Our results are similar to the findings of Mifsud et al. (18), who found no differences between PCOS patients and controls in terms of CAG repeat length; however, among PCOS patients with normal or elevated testosterone concentrations, they found the former to have a significantly smaller CAG repeat number only when the short allele in each patient was considered. In their results, CAG repeat length difference was also 1.6 units on average among patients with normal or elevated testosterone concentrations ( vs , respectively, P¼.004). It is unclear to what extent one CAG repeat (one glutamine unit) affects AR activity. Hsiao et al. (6) reported the identification of an AR coactivator, ARA 24, that can interact with the AR N-terminal polyglutamine region and enhance AR transactivation. They found that the interaction of the AR N-terminal domain with ARA 24 diminishes as polyglutamine length increases. The coactivator activity of ARA 24 to AR also diminished with polyglutamine expansion. They concluded that CAG repeat expansion may result in poorer interaction and weaker activation of the AR coactivator, and could contribute to weaker AR transactivation. Yeh et al. (25) reported that the AR coactivator had been shown to enhance AR-mediated transcriptional activity up to 10- fold, a level that androgen-ar alone cannot reach. Thus, we would infer that even a modest change in repeat number and a subsequent change in the interaction with coactivator could have a large or cumulative effect on AR transcriptional activity. According to our data, progressive expansion of biallelic average length was associated with a linear increase in serum free testosterone concentration. Because an inverse Fertility and Sterility â 2321
5 TABLE 3 Multiple linear regression models with free testosterone as the dependent variable. Variables Standardized b-coefficient P value Unadjusted model (r 2 ¼ 0.095) CAG repeat length Adjusted model I (r 2 ¼ 0.238) Age Body mass index <.001 CAG repeat length Adjusted model II (r 2 ¼ 0.270) Age Body mass index LH/FSH HOMA CAG repeat length Note: FSH, follicle-stimulating hormone; HOMA, homeostatic model assessment; LH, luteinizing hormone. Kim. AR gene CAG repeats in PCOS. Fertil Steril relationship had been shown between CAG repeat length and androgenicity (4, 5), we would infer that the positive correlation found between serum androgen and CAG repeat number is the result of a compensatory change or a feedback mechanism dependent on AR activity; that is, depressed AR activity triggers a mechanism that results in increased androgen secretion and vice versa. However, if serum levels of androgen are related to AR, it is unclear whether the influence of AR on serum androgen is mediated by the hypothalamus-pituitaryovary axis or by its direct effect on ovarian theca cells. In view of the modest correlation (r ¼ 0.309) between them, other factors are probably involved. The transcriptional activation of AR is affected not only by polymorphisms in the AR gene, but also by a number of other factors, including tissue levels of dihydrotestosterone (26), estradiol (27, 28), insulin-like growth factors (29, 30), and AR coactivators (6, 25). Thus, these too may also affect the results. We used free testosterone to determine the presence of biochemical hyperandrogenism. Because a laboratory-specific reference range was not available, we used 2.0 pg/ml as a cut-off value according to Speroff and Fritz (24). Byun et al. (31) investigated the prevalence of PCOS in college students from Korea, and, using the same commercial kit, they defined hyperandrogenism as a free testosterone level above the 95th percentile of that for normally cycling, nonhirsute women. In their results, the mean serum level of free testosterone was pg/ml in 133 normally cycling, nonhirsute women. Likewise, Lee et al. (32) found that the mean serum level of free testosterone was pg/ml in 84 normally cycling, nonhirsute Korean women. Therefore, we think that 2.0 pg/ml, according to Speroff and Fritz (24), is more appropriate as a cut-off reference in our population than the manufacturer s suggestion (2.57 pg/ml in 47 Canadian women, aged from 20 to 39 years). However, we conducted additional analyses using different cut-off values. When the cut-off was increased to 2.57 pg/ml, which was the manufacturer s suggestion, we still observed statistically significant differences. The high free testosterone patients (n ¼ 21) had statistically significantly greater mean lengths than the patients with normal free testosterone (n ¼ 81), as determined using biallelic averages ( vs , P¼.002) and short alleles ( vs , P¼.008) and long alleles ( vs , P¼.013). When the cut-off was decreased to 1.72 pg/ml, which was the mean concentration in PCOS patients in our data, statistically significant differences were still maintained (data not shown). These results may be due to a positive correlation between biallelic average length and free testosterone concentration. In every female cell, one X-chromosome becomes inactive. We did not investigate whether alleles with specific numbers are preferentially inactivated and nonrandom inactivation could have altered our results. But it is doubtful that an X-inactivation feature in peripheral blood leukocytes may reflect the inactivation present in ovarian tissue. In the random inactivation state, averages of both CAG repeat numbers could represent that of target tissue; in our data, the mean biallelic average length was most significantly different between the high and normal free testosterone PCOS patients. The mean age of PCOS patients was statistically significantly lower than that of controls ( vs years, P<.001). This discrepancy was due to the chief complaints of patients and controls. Namely, in women with PCOS, most patients visited the hospital because of irregular menstruation, and most were unmarried, young women. However, the controls largely visited the hospital for cancer screening or infertility and were mainly married women. Nevertheless, we would be surprised if this age discrepancy influenced our results. Our study has not answered the question of whether the AR gene CAG repeat length polymorphism is a direct or major determinant of PCOS or not, but the main findings of our study suggest that the AR gene (CAG) n repeat polymorphism may contribute to the serum concentration of free testosterone in PCOS patients and it may act as a modulator of serum androgen concentration. A subset of PCOS patients with relatively longer CAG repeats in the AR gene (functionally less active AR activity) tend to show higher serum androgen concentration, and they thus may develop symptoms despite decreased AR activity Kim et al. AR gene CAG repeats in PCOS Vol. 90, No. 6, December 2008
6 REFERENCES 1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83: Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar- Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85: Tilley WD, Marcelli M, McPhaul MJ. Recent studies on the androgen receptor: new insights into old questions. Mol Cell Endocrinol 1990;68:C Mahtre AN, Trifiro MA, Kaufman M, Kazemi-Esfarjani P, Figlewicz D, Rouleau G, et al. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat Genet 1993;5: Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production and male infertility. J Clin Endocrinol Metab 1997;82: Hsiao PW, Lin DL, Nakao R, Chang C. The linkage of Kennedy s neuron disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem 1999;274: Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997;94: Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 1997;3: Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57: Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG length varies in a race specific fashion in men without prostate cancer. Urology 1999;53: Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, et al. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. Clin Endocrinol Metab 1996;81: La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352: Yong EL, Loy CJ, Sim KS. Androgen receptor gene and male infertility. Hum Reprod Update 2003;9: Mifsud A, Choon AT, Fang D, Yong EL. Prostate-specific antigen, testosterone, sex-hormone binding globulin and androgen receptor CAG repeat polymorphisms in subfertile and normal men. Mol Hum Reprod 2001;7: Legro RS, Shahbahrami B, Robo RA, Kovacs BW. Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics. Obstet Gynecol 1994;83: Sawaya ME, Shalita AR. Androgen receptor polymorphisms (CAG repeat lengths) in androgenic alopecia, hirsutism and acne. J Cutan Med Surg 1998;3: Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blacjwood MA, Godwin AK, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen receptor CAG repeat. Am J Hum Genet 1999;64: Mifsud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000;85: Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Human Reprod Update 2001;7: Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002;87: Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Human Reprod Update 2003;9: Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21: Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) 1989;31: Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005; Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996;93: Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD. The androgen receptor: genetic considerations on the development and treatment of prostate cancer. J Mol Med 1999;77: Yeh S, Miyamoto H, Shima H, Chang C. From estrogen to androgen receptor: a new pathway for sex hormone in prostate. Proc Natl Acad Sci USA 1998;95: McAbee MD, Doncarlos LL. Estrogen, but not androgens, regulates androgen receptor messenger ribonucleic acid expression in the developing male rat forebrain. Endocrinology 1999;140: Culig Z, Hobisch A, Cronauer M, Hittmair A, Radmayr C, Bartsch G, et al. Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J Urol 1995;13: Gupta C. Modulation of androgen receptor (AR) mediated transcriptional activity by EGF in the developing mouse reproductive tract primary cells. Mol Cell Endocrinol 1999;152: Byun EK, Kim HJ, Oh JY, Hong YS, Sung YA. The prevalence of polycystic ovary syndrome in college students from Seoul. J Korean Soc Endocrinol 2005;20: Lee JY, Cha YJ, Hur SE, Kwon HS, Lee SJ, Sohn IS, et al. Association of the COMT gene polymorphism with the risk of PCOS in Korean women. Kor J Fertil Steril 2006;33: Fertility and Sterility â 2323
METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationClinical and biochemical characteristics of polycystic ovary syndrome in Korean women
Human Reproduction Vol.23, No.8 pp. 1924 1931, 2008 Advance Access publication on June 24, 2008 doi:10.1093/humrep/den239 Clinical and biochemical characteristics of polycystic ovary syndrome in Korean
More informationScreening non-classical 21-hydroxylase gene deficiency from patients diagnosed as polycystic ovary syndrome by gene assay HU Jie, JIAO Kai *
Med J Chin PLA, Vol. 41, No. 3, March 1, 2016 227 21- [ ] (PCOS) 21- (NC-21OHD) 2014 2015 98 PCOS Ferriman-Gallway ( mf-g ) 3 mf-g 0~2 A 3~5 B 6 C30 DNA 5 CYP21A2 8 (ACTH) 30 98 PCOS 5 V281L/920-921insT(P1)
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationIntroduction. Original Article
Iran J Reprod Med Vol. 10. No. 4. pp: 307-314, July 2012 Original Article Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationWHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED
WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationTrinucleotide (CAG) repeat polymorphisms in the androgen receptor gene: molecular markers of risk for male infertility
FERTILITY AND STERILITY VOL. 75, NO. 2, FEBRUARY 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Trinucleotide (CAG)
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationThe Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS
JCEM ONLINE Brief Report Endocrine Research The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS Meredith Brower, Kathleen Brennan, Marita Pall, and Ricardo Azziz Department
More informationAntim ullerian hormone and polycystic ovary syndrome
Antim ullerian hormone and polycystic ovary syndrome Yi-Hui Lin, M.D., a Wan-Chun Chiu, Ph.D., c Chien-Hua Wu, Ph.D., b,e Chii-Ruey Tzeng, M.D., d Chun-Sen Hsu, M.D., a and Ming-I Hsu, M.D. a a Department
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationThe contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome
Human Reproduction vol.14 no.2 pp.307 311, 1999 The contributions of oestrogen and growth factors to increased adrenal androgen secretion in polycystic ovary syndrome E.Carmina 1, F.Gonzalez 2, A.Vidali
More informationNIH Public Access Author Manuscript Fertil Steril. Author manuscript; available in PMC 2011 April 1.
NIH Public Access Author Manuscript Published in final edited form as: Fertil Steril. 2010 April ; 93(6): 1938 1941. doi:10.1016/j.fertnstert.2008.12.138. Prevalence of Hyperandrogenemia in the Polycystic
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationClinical Profile Polycystic Ovarian Syndrome Cases
ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationPOLYCYSTIC OVARY SYNDROME (PCOS) is a genetically
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2745 2749 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-032046 The Prevalence and Features
More informationSCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY
SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY Sahar Mansour Ibrahim, Yossria Ahmed Elsayed, Reda Esmail Reyad 4 and Hanan Fahmy Azzam 1* 2 3 1 Assistant Lecturer,
More informationWhat every dermatologist should know about Polycystic Ovary Syndrome (PCOS)
What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest
More informationCase. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?
Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationValidation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D., a Bart C. J. M. Fauser, M.D., Ph.D., b Joop S. E. Laven,
More informationEndometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2011;38(1):42-46 Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome
More informationSelection criteria of normal controls to predict reliable cut-off values of various endocrine parameters in infertility
J Obstet Gynecol India Vol. 55, No. 1 : January/February 2005 Pg 72-76 ORIGINAL ARTICLE The Journal of Obstetrics and Gynecology of India Selection criteria of normal controls to predict reliable cut-off
More informationX/99/$03.00/0 Vol. 84, No. 5 The Journal of Clinical Endocrinology & Metabolism Copyright 1999 by The Endocrine Society
0021-972X/99/$03.00/0 Vol. 84, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society A New Contributing Factor to Polycystic Ovary Syndrome:
More informationORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome
Malaysian J Pathol 2018; 40(1) : 33 39 ORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome R N Dineshinee NADARAJA MBBS, Pavai STHANESHWAR
More informationOriginal Article Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome *
Received: 17.1.2011 Accepted: 24.7.2011 Original Article Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome * Farahnaz Mardanian 1, Nasrin Heidari 2 Abstract BACKGROUND:
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More information16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA
16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA Katie O Sullivan, MD Adult/Pediatric Endocrinology Fellow University of Chicago ENDORAMA Thursday, September 4th, 2014 Disclosures No financial interests. Will
More informationTHE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE
NSave Nature to Survive 9(1): 01-06, 2014 www.thebioscan.in THE PREVALENCE AND ETIOLOGY OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AS A CAUSE OF FEMALE INFERTILITY IN CENTRAL TRAVANCORE K. ROY GEORGE AND N.
More informationCarotid intima-media thickness in mainly non-obese women with polycystic ovary syndrome and age-matched controls
Original Article Obstet Gynecol Sci 2013;56(4):249-255 http://dx.doi.org/10.5468/ogs.2013.56.4.249 pissn 2287-8572 eissn 2287-8580 Carotid intima-media thickness in mainly non-obese women with polycystic
More informationWEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY
ENDOCRINE REGULATIONS, VOL. 40, 119-123, 2006 119 WEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY J. VRBIKOVA, K. DVORAKOVA, M. HILL, L. STARKA Institute
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationClinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS
International Endocrinology Volume 2012, Article ID 434830, 5 pages doi:10.1155/2012/434830 Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS Kim Forrester-Dumont,
More informationTHYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4
THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4 HOW TO CITE THIS ARTICLE: Sudhanshu Sekhara Nanda, Subhalaxmi Dash, Ashok Behera,
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME 1 2 3 Samdana Wahab, Farnaz, Rukhsana Karim ABSTRACT Objective: To assess the role of Metformin in Polycystic ovarian syndrome (PCOS).
More informationHirsutism: Diagnosis and Treatment. Roger A. Lobo M.D. Columbia University
Hirsutism: Diagnosis and Treatment Roger A. Lobo M.D. Columbia University Signs of hyperandrogenism Acne, Hirsutism, Alopecia All explained by increased androgen production and/or increased sensitivity
More informationIdiopathic hirsutism: an uncommon cause of hirsutism in Alabama
FERTILITY AND STERILITY VOL. 70, NO. 2, AUGUST 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Idiopathic hirsutism:
More informationOriginal Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al
Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationGONADAL FUNCTION: An Overview
GONADAL FUNCTION: An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences Clinical Biochemistry BMLS III & BDS IV VJ Temple 1 What are the Steroid hormones?
More informationObjectives 1. Be able to describe the classic presentation and diagnostic criteria 2. Be able to explain long-term health concerns associated with the diagnosis 3. Understand what basic treatment options
More informationSAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:
Patient: Age: 40 Sex: F MRN: SAMPLE PATIENT Order Number: Completed: Received: Collected: SAMPLE REPORT Progesterone ng/ml 0.34 0.95 21.00 DHEA-S mcg/dl Testosterone ng/ml 48 35 0.10 0.54 0.80 430 Sex
More informationPrevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus
Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus Fahrettin Kelestimur, M.D., a Kürşad Unluhizarci, M.D., a Hür Baybuga,
More informationImpaired glucose tolerance is associated with changes in clinical and biochemical parameters in women with polycystic ovary syndrome
Acta Obstetricia et Gynecologica. 2006; 85: 869 873 ORIGINAL ARTICLE Impaired glucose tolerance is associated with changes in clinical and biochemical parameters in women with polycystic ovary syndrome
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome What is Polycystic Ovarian Syndrome? Polycystic Ovarian Syndrome (PCOS) is characterized by the presence of multiple ovarian cysts and excess androgen production. Clinical Features
More informationCan high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?
ORIGINAL ARTICLE http://dx.doi.org/1.5653/cerm.213.4.3.135 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 213;4(3):135-14 Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationUNDERSTANDING PCOS AND ITS DIAGNOSIS
UNDERSTANDING PCOS AND ITS DIAGNOSIS Anuja Dokras MD, PhD Director PENN PCOS CENTER President, AE-PCOS Society Professor of Obstetrics & Gynecology University of Pennsylvania, Philadelphia, USA is an international
More informationFemale androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010
Female androgen profiles by MS for PCOS patients CS Ho APCCMS 2010, Hong Kong 14 January 2010 873 women with increased serum androgens Androgen-secreting neoplasms 0.2% Classical CAH 0.6% Non-classical
More informationSalivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia
Original Article Salivary Versus Serum Approaches in Assessment of Biochemical Hyperandrogenemia Mohamed Nabih El Gharib, Sahar Mohey El Din Hazaa 1 Departments of Obstetrics and Gynecology, and 1 Clinical
More informationMetfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study
Original Research Article Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Allanki Suneetha Devi 1, Jalem Anuradha 2* 1 Associate Professor, Department of Obstetrics and Gynecology,
More informationInfertility for the Primary Care Provider
Infertility for the Primary Care Provider David A. Forstein, DO FACOOG Clinical Associate Professor Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Disclosure I have
More informationThe serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
Original Article Obstet Gynecol Sci 2018;61(2):242-246 https://doi.org/10.5468/ogs.2018.61.2.242 pissn 2287-8572 eissn 2287-8580 The serum estradiol/oocyte ratio in patients with breast cancer undergoing
More informationAddressing Practice Gaps in PCOS
Addressing Practice Gaps in PCOS PCOS Challenge September 21, 2014 Ricardo Azziz, MD, MPH, MBA President, Georgia Regents University CEO, Georgia Regents Health System Introduction PCOS research began
More information2-Hypertrichosis:- Hypertrichosis is the
Hirsutism And Virilization Hirsutism:- Is the development of androgen-dependent dependent terminal body hair in a woman in places in which terminal hair is normally not found, terminal body hairs are the
More informationCREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University
CREATING A PCOS TREATMENT PLAN Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University PCOS: CREATING A TREATMENT PLAN Good treatment plans are based on sound and complete evaluations History of
More informationPrevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai
Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai Principal Investigator Co- Investigators Consultant Collaborating Hospital Dr. Beena Joshi Dr. Srabani Mukherji
More informationOvarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors
pissn: 2288-6478, eissn: 2288-6761 Original Article Ovarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors Young Shin Han 1, Ah Rha Lee 1, Hee Kyoung Song 1, Jeong In Choi
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationDaily blood hormone levels related to the luteinizing hormone surge in anovulatory cycles
FRTILITY AND STRILITY Copyright 1983 The American Fertility Society Printed in U.8A. Daily blood hormone levels related to the luteinizing hormone surge in anovulatory cycles Chung H. Wu, M.D. * F. Susan
More informationCharacteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population
DOI: 10.1111/j.1471-0528.2009.02347.x www.bjog.org Fertility and assisted reproduction Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale
More informationPrevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study
Original Article Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study Majid Jahangir, MD 1 Seema Qayoom, MD ² Peerzada
More informationManagement of polycystic ovarian syndrome
14 Disorders of male and female sex hormones Management of polycystic ovarian syndrome LI-WEI CHO AND STEPHEN L. ATKIN Patients with polycystic ovarian syndrome can be challenging as they usually present
More informationReproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)
Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD) Pr Sophie Christin-Maitre Reproductive Endocrine Unit, Hôpital Saint-Antoine, AP-HP Université Pierre et Marie Curie INSERM U933 Paris, France
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More informationPOLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015
POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 NO DISCLOSURES PATIENT 26 years old presents with complaint of
More informationAbstract. Introduction. RBMOnline - Vol 10. No Reproductive BioMedicine Online; on web 15 November 2004
RBMOnline - Vol 10. No 1. 2005 100-104 Reproductive BioMedicine Online; www.rbmonline.com/article/1484 on web 15 November 2004 Article Metformin monotherapy in lean women with polycystic ovary syndrome
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Kathleen Colleran, MD Professor of Medicine University of New Mexico HSC Presented for COMM-TC May 4, 2012 Objectives Understand the pathophysiology of PCOS Understand how to
More informationRiju Angik*, Shubhada S. Jajoo, C. Hariharan, Amogh Chimote
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Angik R et al. Int J Reprod Contracept Obstet Gynecol. 2015 Feb;4(1):189-194 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationJMSCR Vol 05 Issue 04 Page April 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.228 Study of Cutaneous Manifestations of
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationSemih Tugrul, M.D., Tayfun Kutlu, M.D., Oya Pekin, M.D., Elif Baglam, M.D., H useyin Kıyak, M.D., and Ozay Oral, M.D.
Clinical, endocrine, and metabolic effects of acarbose, a a-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome Semih Tugrul, M.D., Tayfun Kutlu, M.D., Oya
More informationMetformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study
The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative
More informationlactotrophs 120 min- FSH 60 min- LH Hypothalamus GnRH pituitary Estradiol +/- Progesterone _ FSH L H Ovary Uterus Ovulation Antral follicle >2mm
lactotrophs Hypothalamus GnRH 120 min- 60 min- LH Progesterone _ pituitary L H + Ovary + Estradiol +/- Uterus Antral follicle >2mm Ovulation Preovulatory follicles atresia Follicular phase Luteal phase
More informationThe Relation between Diverse Phenotypes of PCOS with Clinical Manifestations, Anthropometric Indices and Metabolic Characteristics
ORIGINAL ARTICLE The Relation between Diverse Phenotypes of PCOS with Clinical Manifestations, Anthropometric Indices and Metabolic Characteristics Seyedeh Hajar Sharami 1, Zahra Abbasi Ranjbar 2, Forozan
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationAge specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2011;38(2):93-97 Age specific serum anti-müllerian hormone levels in 1,298 Korean women with regular menstruation Ji Hee Yoo, Hye Ok
More informationThe Effect of Vitamin D Replacement Therapy on Serum Leptin and Follicular Growth Pattern in Women with Clomiphene Citrate Resistant Polycystic Ovary
Med. J. Cairo Univ., Vol. 84, No. 2, June: 85-89, 2016 www.medicaljournalofcairouniversity.net The Effect of Vitamin D Replacement Therapy on Serum Leptin and Follicular Growth Pattern in Women with Clomiphene
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationLUCIAN BLAGA UNIVERSITY FROM SIBIU FACULTY OF MEDICINE VICTOR PAPILIAN INSULIN RESISTANCE IN POLYCYSTIC OVARIAN SYNDROME SUMMARY
LUCIAN BLAGA UNIVERSITY FROM SIBIU FACULTY OF MEDICINE VICTOR PAPILIAN INSULIN RESISTANCE IN POLYCYSTIC OVARIAN SYNDROME SUMMARY Scientific coordinator: Dr. Ion Gh. Totoian Ph.D. PhD student: Florina Ioana
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More information